BioSpace News Archive

Harbour BioMed signed an exclusive strategic partnership deal with Sichuan Kelun-Biotech Biopharmaceutical Co. to develop and commercialize an anti-PD-L1 antibody, A167, currently in Phase II development.

Vantage Pharma published a report that reviewed the biopharma and medical technology trends for the year-to-date. Broadly speaking, for biotech companies, venture capital investment is up and mergers and acquisitions is down, while for the medical device company it’s the reverse.

H. Gilbert Welch, a health care policy scholar at Dartmouth College, reportedly plagiarized part of the contents in a 2016 New England Journal of Medicine article. The article focused on breast cancer screening and the increased likelihood of tumors being overdiagnosed.

Some people can be extremely competitive on their quest to obtain promotions and raises, and they aren’t concerned with the colleagues they use in the process. We’ve reviewed what it really means when someone takes credit for your work in the past. Here is how to handle the culprit who’s claiming your efforts!

This past week’s roundup of Movers and Shakers in the biotech industry started with a surprise. Gilead Science’s new(ish) chief medical officer was leaving the company six months after taking over the position.

South San Francisco-based Principia Biopharma is looking to become a publicly traded company and is aiming for a $86 million initial public offering. The company filed its prospectus with the U.S. Securities and Exchange Commission on Aug. 17.

Swiss Pharma giant Roche expanded its presence in China with the approval of its lung cancer drug, Alecesna. Roche said the medication was approved by the China National Drug Administration under a priority review.

Martin Shkreli’s attorney and accomplice in committing wire fraud Evan Greebel has been sentenced to 18 months in prison. Greebel will spend far less time in prison than Shkreli, who was sentenced to seven years behind bars.

According to a recent study, there is a looming gap between the number of employees who claim they value and desire flexibility in the workplace and the overall percentage of workers who say they actually have this flexibility. Harvard Business Review reports that the “flexibility gap” (the number of employees who want flexibility versus those who have it) is around 54%.

Two weeks ago during its quarterly report, Novo Nordisk pointed to positive results in four of 10 Phase IIIa trials with oral semaglutide. This morning, the company revealed that the drug hit the mark in the reduction of blood sugar levels and weight in adults with type 2 diabetes.